Literature DB >> 17509704

The effects of losartan on signal-averaged P wave in patients with atrial fibrillation.

Masahiro Nomura1, Tomohito Kawano, Kimiko Nakayasu, Yutaka Nakaya.   

Abstract

BACKGROUND: Losartan has recently been reported to suppress atrial structural remodeling. However, few reports exist on signal-averaged electrocardiography (ECG) for preventing atrial electrical remodeling. We examined the effect of losartan on atrial electricity by using signal-averaged ECG of P waves.
METHODS: The subjects comprised 40 patients with essential hypertension complicated with symptomatic paroxysmal atrial fibrillation. The patients received pilsicainide for the complication; they were defibrillated and divided into two subgroups for antihypertensive therapy: calcium antagonist-administrated (CB) and losartan-administrated (LOS) groups. We recorded the signal-averaged electrocardiography of P waves and calculated (1) filtered P wave duration (PD), (2) the voltage integral for the entire P wave (integral-p), and (3) the root mean square voltages of the terminal 40, 30, and 20 ms (RMS-40, RMS-30, and RMS-20). Procollagen C propeptide type I (PIP) and A- and B-type natriuretic peptide (ANP and BNP, respectively) levels in the groups were measured before and after antihypertensive agent administration.
RESULTS: RMS-20 increased significantly and PD decreased significantly in the LOS group 24 weeks after antihypertensive drug administration; however, they remained unchanged in the CB group. Integral-p decreased significantly in both groups, and the decrease rate was significantly higher in the LOS group. Serum BNP levels decreased significantly only in the LOS group.
CONCLUSIONS: Losartan inhibits atrial remodeling by inhibiting left atrial fibrosis as indicated by the procollagen C propeptide type I, ANP, and BNP levels. Signal-averaged ECG demonstrated that losartan suppresses atrial fibrillation recurrence by improving atrial conduction disturbance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509704     DOI: 10.1016/j.ijcard.2007.03.106

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Assessment of the Framingham risk factors among ED patients with newly diagnosed atrial fibrillation.

Authors:  Tyler W Barrett; Alan B Storrow; Cathy A Jenkins; Frank E Harrell; John Amdahl; Stephan Russ; Corey M Slovis; Dawood Darbar
Journal:  Am J Emerg Med       Date:  2011-01-03       Impact factor: 2.469

2.  Prevalence of validated risk factors for developing atrial fibrillation--can we identify high-risk ED patients?

Authors:  Tyler W Barrett; Stephanie A Couch; Cathy A Jenkins; Alan B Storrow
Journal:  Am J Emerg Med       Date:  2011-11-17       Impact factor: 2.469

Review 3.  Electrocardiogram (ECG) for the Prediction of Incident Atrial Fibrillation: An Overview.

Authors:  Yoshifusa Aizawa; Hiroshi Watanabe; Ken Okumura
Journal:  J Atr Fibrillation       Date:  2017-12-31

4.  Atrial fibrosis underlying atrial fibrillation (Review).

Authors:  Chang Yi Li; Jing Rui Zhang; Wan Ning Hu; Song Nan Li
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.